Clinical Trials Facilitation Philosophy
medical cannabis
Clinical Trials
Facilitation Philosophy
According to the NIH, “cannabis might be a mediator within the gastrointestinal system, affecting inflammation, motility, and the secretory response.”
The study concluded “that while cannabis might improve UC symptoms, additional research is needed to determine which dose achieves benefits and minimizes adverse effects.”
BRAZIER MDI-P™ by OSJ Rx, is a Metered Dose Inhaler-Pipette for microdosing cannabis in dried flower form. BRAZIER MDI-P™ delivers a thrice filtered 1/8th tsp microdose of botanical cannabis, void of harmful or potentially harmful constituents. The BRAZIER™ system and method addresses inconsistencies in dosing, while mitigating waste. Clinical trials will help physicians more accurately prescribe dosages.
Phase 1
Register eligible patients.
- Register patients of the 43 listed diagnosis
- Monitor executive functions and cognitive behavior with each dose
- Determine dosages based on medical patients feedback
Phase 2
Journal use & effects.
- Journal patients microdosing schedules based on symptoms
- In lieu of large doses, microdoses will be administered as needed
- Determine microdoses based on particular symptoms treated
Phase 3
Standardize microdosing.
- Determine efficacy of BRAZIER MDI-P™ system and method
- Opioid Replacement, Mental Health and Physical Wellness
- Submit FDA application for Rx microdosing standardization